$Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma$

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Carfilzomib can partially overcome resistance in bortezomib-refractory patients and has significant efficacy in bortezomib-naïve pat...

Full description

Bibliographic Details
Main Authors:	Fostier, Karel, De Becker, Ann, Schots, Rik
Format:	Online
Language:	English
Published:	Dove Medical Press 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463411/

Similar Items

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
by: Jain, Salvia, et al.
Published: (2011)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
by: Nooka, Ajay, et al.
Published: (2013)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
by: Atrash, S, et al.
Published: (2015)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
by: Watanabe, Takashi, et al.
Published: (2016)

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
by: Harvey, R Donald
Published: (2014)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
by: Liu, Liping, et al.
Published: (2016)

Targeted treatments for multiple myeloma: specific role of carfilzomib
by: Sugumar, Dhivya, et al.
Published: (2015)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk, Niels WCJ, et al.
Published: (2012)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
by: Jurczyszyn, Artur, et al.
Published: (2014)

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
by: Jakubowiak, A J, et al.
Published: (2013)

A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use
by: Jonsson, F, et al.
Published: (2015)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Alegre, Adrian, et al.
Published: (2011)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael, M, et al.
Published: (2010)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
by: Yang, Wen-Chi, et al.
Published: (2015)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
by: Terpos, Evangelos, et al.
Published: (2013)

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
by: Badros, A Z, et al.
Published: (2013)

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
by: Hu, Bo, et al.
Published: (2013)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
by: Rosenthal, A, et al.
Published: (2016)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Cerchione, Claudio, et al.
Published: (2016)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
by: Chen, Christine, et al.
Published: (2009)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Siegel, D S, et al.
Published: (2014)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Siegel, D S, et al.
Published: (2014)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
by: Kumar, S K, et al.
Published: (2015)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
by: Ahn, Jae-Sook, et al.
Published: (2014)

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
by: Kim, Hyo Jung, et al.
Published: (2015)

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
by: Redic, Kimberly A, et al.
Published: (2016)

Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
by: Hájek, Roman, et al.
Published: (2012)

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
by: San-Miguel, Jesus F., et al.
Published: (2016)

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
by: Matsue, Kosei, et al.
Published: (2015)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
by: Mu, Song, et al.
Published: (2015)

Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
by: Hobeika, Liliane, et al.
Published: (2014)

KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models
by: Riz, Irene, et al.
Published: (2015)

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
by: Gao, Lu, et al.
Published: (2015)

Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
by: Luo XW, et al.
Published: (2018-08-01)

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
by: Dimopoulos, M A, et al.
Published: (2014)

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity
by: Cornell, R F, et al.
Published: (2016)

A case report of immunosuppression-related Kaposi’s sarcoma after autologous stem cell transplantation
by: Heyrman, Bert, et al.
Published: (2016)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
by: Thumallapally, Nishitha, et al.
Published: (2016)

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
by: Meletios Dimopoulos, et al.
Published: (2018-04-01)

Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model
by: Nur, Haneen, et al.
Published: (2013)